Patents by Inventor Yvonne WETTERGREN

Yvonne WETTERGREN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADMINISTRATION REGIME
    Publication number: 20230220490
    Abstract: A method for determining a folate substance administration regime is disclosed. The method comprises: quantifying, in a sample drawn from a patient, the expression level of at least one of the genes SLC46A1, SLC19A1, FPGS, ABCC3, MTHFD1L, GGH, MTHFD1, MTFMT, and ATIC; and establishing whether the expression level is high or low. A high expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate and/or a folate substance upstreams of [6R]-methylenetetrahydrofolate in the metabolic pathway. A low expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate. Also disclosed is a kit for determining such a folate substance administration regime.
    Type: Application
    Filed: February 24, 2023
    Publication date: July 13, 2023
    Applicant: Isofol Medical AB
    Inventors: Yvonne Wettergren, Elisabeth Odin
  • Methods for increasing blood plasma 2?-deoxyuridine (dUrd) and thymidylate synthase inhibition
    Patent number: 11389452
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: July 19, 2022
    Assignee: Isofol Medical AB
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION
    Publication number: 20200330468
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Application
    Filed: May 4, 2020
    Publication date: October 22, 2020
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • Methods for increasing blood plasma 2?-deoxyuridine (dUrd) and thymidylate synthase inhibition
    Patent number: 10639311
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: May 5, 2020
    Assignee: Isofol Medical AB
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • ADMINISTRATION REGIME
    Publication number: 20200040406
    Abstract: A method for determining a folate substance administration regime is disclosed. The method comprises: quantifying, in a sample drawn from a patient, the expression level of at least one of the genes SLC46A1, SLC19A1, FPGS, ABCC3, MTHFD1L, GGH, MTHFD1, MTFMT, and ATIC; and establishing whether the expression level is high or low. A high expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate and/or a folate substance upstreams of [6R]-methylenetetrahydrofolate in the metabolic pathway. A low expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate. Also disclosed is a kit for determining such a folate substance administration regime.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Applicant: Isofol Medical AB
    Inventors: Yvonne Wettergren, Elisabeth Odin
  • Administration regime
    Patent number: 10487364
    Abstract: A method for determining a folate substance administration regime is disclosed. The method comprises: quantifying, in a sample drawn from a patient, the expression level of at least one of the genes SLC46A1, SLC19A1, FPGS, ABCC3, MTHFD1 L, GGH, MTHFD1, MTFMT, and ATIC; and establishing whether the expression level is high or low. A high expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate and/or a folate substance upstreams of [6R]-methylenetetrahydrofolate in the metabolic pathway. A low expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate. Also disclosed is a kit for determining such a folate substance administration regime.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 26, 2019
    Assignee: ISOFOL MEDICAL AB
    Inventors: Yvonne Wettergren, Elisabeth Odin
  • METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION
    Publication number: 20190240224
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Application
    Filed: February 4, 2019
    Publication date: August 8, 2019
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • Methods for increasing blood plasma 2?-deoxyuridine (dUrd) and thymidylate synthase inhibition
    Patent number: 10292984
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: May 21, 2019
    Assignee: Isofol Medical AB
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION
    Publication number: 20180289711
    Abstract: The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.
    Type: Application
    Filed: February 9, 2018
    Publication date: October 11, 2018
    Inventors: Göran U. Carlsson, Bengt Gustavsson, Elisabeth Odin, Yvonne Wettergren, Anders Vedin
  • ADMINISTRATION REGIME
    Publication number: 20160340739
    Abstract: A method for determining a folate substance administration regime is disclosed. The method comprises: quantifying, in a sample drawn from a patient, the expression level of at least one of the genes SLC46A1, SLC19A1, FPGS, ABCC3, MTHFD1 L, GGH, MTHFD1, MTFMT, and ATIC; and establishing whether the expression level is high or low. A high expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate and/or a folate substance upstreams of [6R]-methylenetetrahydrofolate in the metabolic pathway. A low expression level of at least one of said genes determines that said folate substance administration regime involves the administration of [6R]-methylenetetrahydrofolate. Also disclosed is a kit for determining such a folate substance administration regime.
    Type: Application
    Filed: January 30, 2015
    Publication date: November 24, 2016
    Inventors: Yvonne WETTERGREN, Elisabeth ODIN